Icon Plc (NASDAQ:ICLR) – Investment analysts at KeyCorp decreased their Q4 2017 earnings per share (EPS) estimates for shares of Icon in a research report issued on Tuesday. KeyCorp analyst D. Hooker now anticipates that the medical research company will post earnings of $1.39 per share for the quarter, down from their prior forecast of $1.41. KeyCorp has a “Buy” rating and a $130.00 price objective on the stock.
Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company had revenue of $440.30 million during the quarter, compared to analysts’ expectations of $438.09 million. During the same quarter in the prior year, the company posted $1.19 EPS. The business’s revenue was up 4.8% on a year-over-year basis.
Icon (NASDAQ ICLR) opened at $113.27 on Friday. Icon has a one year low of $76.46 and a one year high of $124.48. The stock has a market cap of $6,211.78, a price-to-earnings ratio of 22.02, a PEG ratio of 1.63 and a beta of 0.56. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31.
Several institutional investors have recently made changes to their positions in ICLR. Schwab Charles Investment Management Inc. increased its position in shares of Icon by 39.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 16,713 shares of the medical research company’s stock worth $1,635,000 after purchasing an additional 4,692 shares in the last quarter. Legal & General Group Plc increased its position in shares of Icon by 35.9% during the 2nd quarter. Legal & General Group Plc now owns 7,592 shares of the medical research company’s stock worth $743,000 after purchasing an additional 2,006 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Icon by 26.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 37,723 shares of the medical research company’s stock worth $3,690,000 after purchasing an additional 7,860 shares in the last quarter. Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Icon during the 2nd quarter worth about $208,000. Finally, Seven Eight Capital LP increased its position in shares of Icon by 750.0% during the 2nd quarter. Seven Eight Capital LP now owns 8,500 shares of the medical research company’s stock worth $831,000 after purchasing an additional 7,500 shares in the last quarter. Institutional investors and hedge funds own 89.66% of the company’s stock.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.